Press Release

•

Research & Insights

4 minutes to read

MitoQ New Zealand Partners NUS Medicine to Advance Healthy Ageing and Mitochondrial Research

Singapore, 6 May 2026 - MitoQ New Zealand has entered into a research partnership with the Yong Loo Lin School of Medicine, National University of Singapore, to support new scientific research into mitochondrial health, biological ageing and healthy longevity.

The partnership will examine MitoQ® (mitoquinol mesylate), a mitochondria-targeted antioxidant, within a broader research programme focused on healthy ageing. The collaboration will also explore how biological ageing clocks may help researchers better assess health and nutrition interventions over shorter timeframes than conventional long-term studies.

Mitochondria are often described as the energy centres of the cell. They play an important role in cellular energy production and are increasingly studied in relation to ageing biology, resilience and long-term health. Through this partnership, MitoQ New Zealand and NUS Medicine aim to contribute to a stronger scientific understanding of mitochondrial function and its relevance to healthy ageing.

The research collaboration was formalised through a Memorandum of Understanding between Mr Mahara Inglis, Chief Executive Officer of MitoQ New Zealand, and Associate Professor Jan Gruber from the Department of Biochemistry and the Healthy Longevity Translational Research Programme at NUS Medicine. The signing was commemorated at the Singapore-New Zealand Leadership Forum in Singapore on 4 May 2026.

The partnership was also acknowledged during the official visit of New Zealand Prime Minister Rt Hon Christopher Luxon to Singapore, alongside The Hon Nicola Willis, Minister of Finance, and The Hon Todd McClay, Minister for Trade and Investment. The collaboration sits within the broader Singapore-New Zealand Comprehensive Strategic Partnership, where science, technology and innovation are key areas of cooperation.

Associate Professor Jan Gruber, who will lead the research, said:

“Our goal is to strengthen the evidence base on how widely used supplements work, so that individuals can make more informed, evidence-driven decisions about ageing well. This research aligns with Singapore’s long-term priorities in healthy ageing, disease prevention and productive longevity, contributes to Singapore-led research on biological ageing and supports longer-term international collaboration in healthy longevity science.”

A Research Partnership Focused on Biological Ageing

The research will apply biological ageing clocks alongside other health measures, including vascular and cognitive markers. Biological ageing clocks are tools used in research to help assess biological ageing patterns and related health indicators.

The programme will be conducted in two phases.

The first phase, expected to run from May to September 2026, will analyse samples from an existing three-month study involving 150 participants. Researchers will use blood samples and the LinAge3 biological ageing clock, an algorithm-based tool designed to assess biological ageing and support the prediction of longer-term health outcomes.

The second phase, beginning in July 2026, will involve a controlled trial with approximately 100 participants. This phase will combine questionnaire-based assessments with epigenetic clocks and the LinAge biological ageing clock. Researchers will also analyse multiple molecular layers from blood samples to validate the findings.

The research is expected to be completed in December 2027. Findings from the collaboration are expected to help guide future clinical research into biological ageing clocks and their potential use in assessing nutrition and supplementation strategies.

MitoQ’s Commitment to Mitochondrial Science

For MitoQ New Zealand, the partnership reflects a long-standing commitment to mitochondrial research, scientific collaboration and evidence-led innovation.

Dr Siobhan Mitchell, Chief Scientific Officer at MitoQ New Zealand, said:

“Scientific research and R&D have always been at the core of MitoQ, and for decades we have focused on how mitochondria influence health and ageing. We are delighted to partner with Associate Professor Jan Gruber and his team at NUS Medicine to deepen the understanding of the role that mitochondria-targeted interventions like MitoQ® may play in supporting healthy ageing.”

MitoQ® is a mitochondria-targeted antioxidant developed from research into mitochondrial function and oxidative stress. As a cellular health supplement brand, MitoQ focuses on supporting mitochondrial health, cellular energy, vitality and healthy ageing as part of a consistent wellness routine.

Why This Research Matters

Healthy ageing is becoming an increasingly important area of scientific focus as populations live longer and place greater emphasis on maintaining health, function and independence over time.

By combining NUS Medicine’s expertise in biological ageing research with MitoQ New Zealand’s focus on mitochondrial science, the partnership aims to contribute to a more rigorous understanding of how mitochondrial health can be studied in the context of ageing and longevity.

For individuals interested in cellular health, the collaboration reinforces the importance of evidence-led research, responsible supplementation and a long-term view of healthy ageing.

Disclaimer: MitoQ® is a health supplement. It is not intended to diagnose, treat, cure or prevent any disease. Health supplements in Singapore must not be promoted for any specific medicinal purpose, including treatment or prevention of disease.

Learn more about MitoQ and mitochondrial health at https://sg.mitoq.com.

This article is adapted from an announcement published by NUS Medicine on 6 May 2026.

About National University of Singapore (NUS)

The National University of Singapore (NUS) is Singapore’s flagship university, which offers a global approach to education, research, and entrepreneurship, with a focus on Asian perspectives and expertise. We have 15 colleges, faculties, and schools across three campuses in Singapore, with more than 40,000 students from 100 countries enriching our vibrant and diverse campus community. We have also established our NUS Overseas Colleges programme in more than 15 cities around the world. Our multidisciplinary and real-world approach to education, research, and entrepreneurship enables us to work closely with industry, governments, and academia to address crucial and complex issues relevant to Asia and the world.

Researchers in our faculties, 30 university-level research institutes, research centres of excellence and corporate labs focus on themes that include energy; environmental and urban sustainability; treatment and prevention of diseases; active ageing; advanced materials; risk management and resilience of financial systems; Asian studies; and Smart Nation capabilities such as artificial intelligence, data science, operations research, and cybersecurity. For more information on NUS, please visit www.nus.edu.sg.

About the NUS Yong Loo Lin School of Medicine (NUS Medicine)

The NUS Yong Loo Lin School of Medicine is Singapore’s first and largest medical school. Our enduring mission centres on nurturing highly competent, values-driven, and inspired healthcare professionals to transform the practice of medicine and improve health around the world. Through a dynamic and future-oriented five-year curriculum that is inter-disciplinary and inter-professional in nature, our students undergo a holistic learning experience that exposes them to multiple facets of healthcare and prepares them to become visionary leaders and compassionate doctors and nurses of tomorrow.

Since the School’s founding in 1905, more than 12,0000 graduates have passed through our doors. In our pursuit of health for all, our strategic research programmes focus in innovative, cutting-edge biomedical research with collaborators around the world to deliver high impact solutions to benefit human lives. The School is the oldest institution of higher learning in the National University Health System. It is one of the leading medical schools in Asia and ranks among the best in the world (Times Higher World University Rankings 2026 by subject and the Quacquarelli Symonds (QS) World University Rankings by Subject 2026). For more information about NUS Medicine, please visit https://medicine.nus.edu.sg/.

About MitoQ New Zealand

MitoQ is a New Zealand cellular health supplements brand and the inventor of MitoQ® (mitoquinol mesylate), a world-first mitochondria-targeted antioxidant developed from research into mitochondrial function and oxidative stress. Supported by more than three decades of scientific research and clinical data, including over 1,000 peer-reviewed scientific publications and 29 clinical trials involving MitoQ® (mitoquinol mesylate) and related applications, MitoQ focuses on supporting health at the cellular level, particularly mitochondrial health, energy, vitality and healthy ageing. For more information about MitoQ, please visit https://www.mitoq.com/.

WRITTEN BY

MitoQ Singapore